A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years
- 8 November 2025
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (2) , 106-114.e5
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With PolyangiitisJAMA Network Open, 2022
- Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: systematic bias assessment of ovarian cancer treatment effectivenessJournal of Clinical Epidemiology, 2022
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2021
- Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myelomaCancer, 2020
- A causal framework for classical statistical estimands in failure‐time settings with competing eventsStatistics in Medicine, 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysisJournal of Geriatric Oncology, 2020
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyThe Lancet, 2019
- Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myelomaAnnals of Hematology, 2018
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017
- Autologous stem cell transplant for multiple myeloma patients 70 years or olderBone Marrow Transplantation, 2016